January 25, 2018 by Melanie Gross

I recently co-authored a paper reviewing weight-of-evidence (WoE) approaches for the assessment of endocrine disrupting properties. The aim of this paper was to review examples of endocrine-specific WoE evaluations and distil key recommendations for WoE evaluations within a European regulatory context.

The full paper is available as an open access article in Regulatory Toxicology and Pharmacology, Volume 91, December 2017, Pages 20-28.